Watch the webcasts from our industry partners' Satellite Symposia.
30 Mar 2023
Daiichi Sankyo and AstraZeneca
Addressing the unmet need in mNSCLC: Treating progression after immunochemotherapy
- Welcome and introduction
M. Perol - Strategies for treating patients with progression after immunochemotherapy
M. Perol - Antibody-drug conjugates: Current perspectives
A. Passaro - Antibody-drug conjugates: Future considerations
E. Felip - Audience Q&A and closing remarks
M. Perol
Janssen Pharmaceuticals
Exploring clinical perspectives in advanced EGFR-mutant NSCLC: How far we have come
- Welcome and introduction
Alfredo Addeo - Translating data into clinical practice in EGFR-mutant NSCLC
Zopia Piotrowska - Practical data applications in EGFR exon20ins-mutant NSCLC
Nicolas Girard - Q&A and closing remarks
Enriqueta Felip
31 Mar 2023
GSK
Latest scientific advances and investigational approaches with IO in NSCLC
- Introduction
D. Planchard - The latest in checkpoint inhibition
N. Leighl - Advances in novel IO combinations
N. Reinmuth - Ongoing IO trials & potential implications
D. Planchard - Panel Discussion and Q&A
D. Planchard
Novocure GmbH
The evolving role of tumor treating fields therapy in thoracic oncology
- Welcome and introduction
Corey Langer - The practice-changing experience with TTFields therapy in glioblastoma
Andreas Hottinger - The expanding experience with TTFields therapy in pleural mesothelioma
Federica Grosso - Is there a place for TTFields therapy in non-small cell lung cancer?
Corey Langer - Panel discussion: Evolving role of TTFields therapy in solid tumors
Andreas Hottinger - Concluding remarks and close
Corey Langer